Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q18359206> ?p ?o }
Showing triples 1 to 21 of
21
with 100 triples per page.
- Q18359206 subject Q7145142.
- Q18359206 subject Q8758634.
- Q18359206 abstract "PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.".
- Q18359206 wikiPageWikiLink Q14907685.
- Q18359206 wikiPageWikiLink Q173235.
- Q18359206 wikiPageWikiLink Q18031401.
- Q18359206 wikiPageWikiLink Q18349874.
- Q18359206 wikiPageWikiLink Q18386159.
- Q18359206 wikiPageWikiLink Q18393205.
- Q18359206 wikiPageWikiLink Q1988322.
- Q18359206 wikiPageWikiLink Q202517.
- Q18359206 wikiPageWikiLink Q206921.
- Q18359206 wikiPageWikiLink Q30612.
- Q18359206 wikiPageWikiLink Q424960.
- Q18359206 wikiPageWikiLink Q5072487.
- Q18359206 wikiPageWikiLink Q524353.
- Q18359206 wikiPageWikiLink Q7145142.
- Q18359206 wikiPageWikiLink Q7180990.
- Q18359206 wikiPageWikiLink Q8758634.
- Q18359206 comment "PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.".
- Q18359206 label "PF-05089771".